Previous 10 | Next 10 |
Alector press release (NASDAQ:ALEC): Q4 GAAP EPS of -$0.68 misses by $0.75. Revenue of $14M (+188.7% Y/Y) misses by $69.82M. For further details see: Alector GAAP EPS of -$0.68 misses by $0.75, revenue of $14M misses by $69.82M
CTAD and SITC presentations in fourth quarter highlight progress across immuno-neurology and immuno-oncology portfolio Over $900 million in pro forma cash, cash equivalents and investments supports execution of clinical, research and operational goals Steady continue...
Bank of America analyst Jill Carey Hall highlighted 28 Buy-rated "quality" small cap stocks in the Russell 2000 index (RTY), with 20 of them on the "growth" benchmark. "Quality is typically one of the most-rewarded styles during Late Cycle regimes/Fed hiking cycles, the Russell 2000 Gro...
Alector (NASDAQ:ALEC) appoints Marc Grasso, M.D.,as CFO and will play a critical role in supporting corporate strategy. He will report to Arnon Rosenthal, Ph.D., CEO and brings extensive biotechnology industry leadership experience, including a successful track record in financ...
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Office...
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Sara Kenkare-Mitra, Ph.D., the comp...
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Sara Kenkare-Mitra, Ph.D., as President and Head of Research and Development. In this newl...
Progranulin Levels Increase to Normal Ranges Multiple Biomarkers of Disease Showed Improvement from Baseline with AL001 Treatment, Including GFAP, a Prognostic Marker for FTD Associated with Brain Atrophy FTD-GRN Patients Showed a Slowing of Clinical Progression with A...
Preclinical Oncology Program Highlights Alector’s Expertise in Harnessing Components of the Innate Immune System to Impact Disease AL009 Targets Innate Immune Checkpoint Receptors, Blocks Immune Suppression of Tumor Cells and Activates Potent Anti-Cancer Immune Resp...
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, shared data from its AL003 and AL101 programs in poster presentations at the 14th Clinical Trials on Alzheimer's Disease (CTA...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...